OBJECTIVES: To evaluate the efficacy of modafinil combined with cognitive behavioral therapy (CBT) for treatment of methamphetamine (MA) dependence among HIV+ gay men. METHODS: In a single blind trial, modafinil was administered for 12 weeks, followed by a 4-week placebo phase. CBT was conducted for 18 sessions over the 16-week study. Primary outcome measures were self-reported use of days per week plus urine toxicology assays. Additional measures included the Beck Depression Inventory, Cravings Scale, and O/C Crystal Use Scale. Response was defined as > 50% decline in days used per week. Thirteen patients were enrolled over an 18-month period. RESULTS: Ten patients (77%) completed the trial, although two discontinued modafinil due to side effects. Six of the ten study completers reduced their MA use by > 50%. CONCLUSIONS: These preliminary results suggest good retention using combined medication and psychotherapy, and support further examination of modafinil and CBT in double-blind placebo controlled trials.
RCT Entities:
OBJECTIVES: To evaluate the efficacy of modafinil combined with cognitive behavioral therapy (CBT) for treatment of methamphetamine (MA) dependence among HIV+ gay men. METHODS: In a single blind trial, modafinil was administered for 12 weeks, followed by a 4-week placebo phase. CBT was conducted for 18 sessions over the 16-week study. Primary outcome measures were self-reported use of days per week plus urine toxicology assays. Additional measures included the Beck Depression Inventory, Cravings Scale, and O/C Crystal Use Scale. Response was defined as > 50% decline in days used per week. Thirteen patients were enrolled over an 18-month period. RESULTS: Ten patients (77%) completed the trial, although two discontinued modafinil due to side effects. Six of the ten study completers reduced their MA use by > 50%. CONCLUSIONS: These preliminary results suggest good retention using combined medication and psychotherapy, and support further examination of modafinil and CBT in double-blind placebo controlled trials.
Authors: Steven Shoptaw; Alice Huber; James Peck; Xiaowei Yang; Juanmei Liu; John Roll; Benjamin Shapiro; Erin Rotheram-Fuller; Walter Ling Journal: Drug Alcohol Depend Date: 2006-04-18 Impact factor: 4.492
Authors: Charles A Dackis; Kyle M Kampman; Kevin G Lynch; Helen M Pettinati; Charles P O'Brien Journal: Neuropsychopharmacology Date: 2005-01 Impact factor: 7.853
Authors: Y N Wong; D Simcoe; L N Hartman; W B Laughton; S P King; G C McCormick; P E Grebow Journal: J Clin Pharmacol Date: 1999-01 Impact factor: 3.126
Authors: Ahmed M Elkashef; Richard A Rawson; Ann L Anderson; Shou-Hua Li; Tyson Holmes; Edwina V Smith; Nora Chiang; Roberta Kahn; Frank Vocci; Walter Ling; Valerie J Pearce; Michael McCann; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Dennis Weis Journal: Neuropsychopharmacology Date: 2007-06-20 Impact factor: 7.853
Authors: Radha Rajasingham; Matthew J Mimiaga; Jaclyn M White; Megan M Pinkston; Rachel P Baden; Jennifer A Mitty Journal: AIDS Patient Care STDS Date: 2011-11-09 Impact factor: 5.078
Authors: Keith G Heinzerling; Aimee-Noelle Swanson; Soeun Kim; Lisa Cederblom; Ardis Moe; Walter Ling; Steven Shoptaw Journal: Drug Alcohol Depend Date: 2010-01-25 Impact factor: 4.492